NDA 213931 · Ardelyx INC
Xphozah
Tenapanor Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: Jun 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 17, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
38
15 Phase 3, 2 recruiting
FAERS reports
23
18 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 27, 2025.
XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy ( 1 ).
Mechanism: Tenapanor is a locally acting inhibitor that targets the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the epithelium of the small intestine and colon. Inhibition of NHE3 by tenapanor results in reduced sodium absorption and decreased phosphate absorption by reducing phosphate permeability through the paracellular pathway.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 17, 2023 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLetterLabelReview
3 products under this application
- XPHOZAH · TENAPANOR HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
- XPHOZAH · TENAPANOR HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Discontinued
- XPHOZAH · TENAPANOR HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tenapanor" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisPivotal-lookingCompleted
ArdelyxIndustry
NCT03427125 · 1,559 participants · Start Jan 8, 2018 · Primary completion Nov 15, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: The Bronx, New York; Winston-Salem, North Carolina
- A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsPivotal-lookingRecruiting
ArdelyxIndustry
NCT07382167 · 692 participants (planned) · Start Jan 13, 2026 · Primary completion Feb 26, 2027
Drug: Tenapanor 5 mg BID; Tenapanor 25 mg BID and 2 more · For: Chronic Idiopathic Constipation (CIC)
Sites: Foley, Alabama; Saraland, Alabama; Chandler, Arizona · 109 sites in all
- A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-CPivotal-lookingCompleted
ArdelyxIndustry
NCT02621892 · 606 participants · Start Oct 2015 · Primary completion Mar 2017
Drug: Tenapanor; Placebo · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 111 sites in all
- A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-CPivotal-lookingCompleted
ArdelyxIndustry
NCT02686138 · 593 participants · Start Dec 2015 · Primary completion Aug 2017
Drug: Tenapanor; Placebo · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Dothan, Alabama; Foley, Alabama; Huntsville, Alabama · 117 sites in all
- The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)Pivotal-lookingCompleted
ArdelyxIndustry
NCT01923428 · 356 participants · Start Aug 2013 · Primary completion Oct 2014
Drug: AZD1722; Placebo · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Boulder, Colorado; Greensboro, North Carolina; Winston-Salem, North Carolina · 4 sites in all
- Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaPivotal-lookingCompleted
ArdelyxIndustry
NCT04549597 · 333 participants · Start Nov 20, 2020 · Primary completion Oct 13, 2021
Drug: Tenapanor · For: Chronic Kidney Disease Requiring Chronic Dialysis; Hyperphosphatemia
Sites: Lauderdale Lakes, Florida
- A Long-Term Safety Study of Tenapanor for the Treatment of IBS-CPivotal-lookingCompleted
ArdelyxIndustry
NCT02727751 · 312 participants · Start Mar 2016 · Primary completion Oct 2017
Drug: Tenapanor · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Miami, Florida
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyPivotal-lookingCompleted
ArdelyxIndustry
NCT03824587 · 236 participants · Start Feb 28, 2019 · Primary completion Jul 17, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Beverly Hills, California · 48 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea3
- anaemia2
- asthenia2
- cough2
- covid-192
- decreased appetite2
- diarrhoea2
- drug ineffective2
- drug ineffective for unapproved indication2
- fatigue2
- gastrointestinal disorder2
- pre-existing condition improved2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xphozah (Tenapanor HCl)
2024 spending
$122M
Beneficiaries
9,953
34,525 claims
Per beneficiary
$12,208
$48.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,338,817 |
| 2024 | $121,506,333 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.
Sprague SM, Weiner DE, Tietjen DP, et al. · Kidney360 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P, Camilleri M, Burr NE, et al. · Lancet Gastroenterol Hepatol 2019 · Research Support, N.I.H., Extramural, Systematic Review
- Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
Lin T, Al-Makki A, Shepler B · J Pharm Pharm Sci 2022 · Systematic Review
- Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
Johansson S, Rosenbaum DP, Ahlqvist M, et al. · Clin Pharmacol Drug Dev 2017 · Clinical Trial, Phase I
- Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
Luo H, Feng J, Zhang Y, et al. · Ther Apher Dial 2023 · Meta-Analysis, Systematic Review
- Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.
Brenner DM, Sayuk GS, Cash BD, et al. · Dig Dis 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Ardelyx INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.